Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | ROS1 |
Variant | D2113G |
Impact List | missense |
Protein Effect | gain of function |
Gene Variant Descriptions | ROS1 D2113G lies within the protein kinase domain of the Ros1 protein (UniProt.org). D2113G results in increased Ros1 activity, phosphorylation of Shp2 and Stat3, and colony formation in culture (PMID: 37587872) and has been demonstrated to confer resistance to ROS1 tyrosine kinase inhibitors in the context of ROS1 fusions in culture (PMID: 26372962). |
Associated Drug Resistance | Y |
Category Variants Paths |
ROS1 mutant ROS1 act mut ROS1 D2113G |
Transcript | NM_002944.3 |
gDNA | chr6:g.117310177T>C |
cDNA | c.6338A>G |
Protein | p.D2113G |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_002944 | chr6:g.117310177T>C | c.6338A>G | p.D2113G | RefSeq | GRCh38/hg38 |
NM_002944.2 | chr6:g.117310177T>C | c.6338A>G | p.D2113G | RefSeq | GRCh38/hg38 |
NM_002944.3 | chr6:g.117310177T>C | c.6338A>G | p.D2113G | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
ROS1 D2113G | Advanced Solid Tumor | sensitive | Crizotinib | Preclinical - Cell culture | Actionable | In a preclinical study, Xalkori (crizotinib) inhibited proliferation of transformed cells expressing ROS1 D2113G in culture (PMID: 37587872). | 37587872 |
ROS1 D2113G | Advanced Solid Tumor | sensitive | Lorlatinib | Preclinical - Cell culture | Actionable | In a preclinical study, Lorbrena (lorlatinib) inhibited proliferation of transformed cells expressing ROS1 D2113G in culture (PMID: 37587872). | 37587872 |
ROS1 D2113G | Advanced Solid Tumor | sensitive | Selumetinib | Preclinical - Cell culture | Actionable | In a preclinical study, Koselugo (selumetinib) inhibited proliferation of transformed cells expressing ROS1 D2113G in culture (PMID: 37587872). | 37587872 |
ROS1 D2113G | Advanced Solid Tumor | sensitive | Repotrectinib | Preclinical - Cell culture | Actionable | In a preclinical study, Augtyro (repotrectinib) inhibited proliferation of transformed cells expressing ROS1 D2113G in culture (PMID: 37587872). | 37587872 |
ROS1 D2113G | Advanced Solid Tumor | sensitive | TNO155 | Preclinical - Cell culture | Actionable | In a preclinical study, TNO155 inhibited proliferation of transformed cells expressing ROS1 D2113G in culture (PMID: 37587872). | 37587872 |
ROS1 D2113G | Advanced Solid Tumor | sensitive | RMC-4550 | Preclinical - Cell culture | Actionable | In a preclinical study, RMC-4550 inhibited proliferation of transformed cells expressing ROS1 D2113G in culture (PMID: 37587872). | 37587872 |
ROS1 D2113G | Advanced Solid Tumor | sensitive | NUV-520 | Preclinical - Cell culture | Actionable | In a preclinical study, NUV-520 inhibited proliferation of transformed cells expressing ROS1 D2113G in culture (PMID: 37587872). | 37587872 |